Page Title
Drug Development Pipeline
GS-5745
Status
DiscontinuedTherapeutic Approach
Anti-Inflammatory
GS-5745 is an antibody that may help reduce inflammation in the lungs, leading to improved lung function in people with CF.
Status
A phase 2 study to test the effectiveness of GS-5745 in adults with CF was stopped in 2017. The decision to discontinue was not due to any safety concerns in the study.
No further clinical development in CF is planned at this time.
Sponsor
This program was sponsored by Gilead. It was conducted within the Therapeutics Development Network.
CONTACT THE CLINICAL TRIAL NAVIGATOR
Get personalized assistance and answers to your clinical trial questions.
Learn MoreSign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.
Learn More